Mersana Therapeutics Inc (NASDAQ: MRSN) has been on an uptrend for the past week and was up by 6.84% in Friday’s session. This followed the company’s announcement that it had appointed Martin Huber to its board.

Commenting on the announcement, President Anna Protopapas stated that, the company was excited to have Dr. Martin in the board. She added that Dr. Martin had a good track record in transformational medicine for patients suffering from lung and ovarian cancer. She further stated that his experience was needed in the company’s proof of concept for XMR-1536.

In his previous work engagements, Dr. Martin Huber worked as the VP and Chief Medical Officer at TESARO Inc.  He used his time there to help in the expansion of the niraparib program. He was also instrumental in the advancement of the company’s immune-oncology agents. He had also exercised his skills at Merck Research Laboratories and at the University of Texas MD Anderson Cancer Center. 

Commenting on the company’s current studies, Dr. Huber stated that it is currently in phase 1 of its XMT-1536 that targets NaPi2b and that it was promising. The company stated that the results showed confirmed responses in highly-pretreated populations. Dr. Huber also stated that the company’s Immunosynthen and Dolasynthen platforms could help push the science of ADCs much further. He added that he was looking forward to helping the company come up with new ADC therapies for people struggling with cancer.  

Looking at its price action, MRSN is in an uptrend. It opened the day at $8.61 and traded between a low of $8.48 and a high of $9.43, before closing at $9.06. Volumes in the day stood at 761.73k.

About Mersana Therapeutics Inc

Mersana Therapeutics Inc is a clinical-stage biopharma that makes antibody cancer treatments. Its core operations are in Cambridge, Massachusetts.